Skip to main content
. 2014 May 29;111(3):506–514. doi: 10.1038/bjc.2014.289

Figure 1.

Figure 1

Expressions of candidate antigens in the cisplatin-resistant HNSCC cell line Detroit562. (A) Cisplatin-resistant Detroit562 were generated and validated by testing their viability against that of the parental cell line in response to cisplatin treatment, at the indicated doses. Statistical analysis was performed using two-way analysis of variance. Data represent means±s.e.m. (B) Expression analyses of CD10, CD15s, CD146 and CD282 by flow cytometry in cisplatin-resistant Detroit562 and the parental cells. The percentages of positive subpopulations are indicated; **P<0.01; n.s., not significant. (C) The interdependence of the four markers.